Cargando…
Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report
BACKGROUND: Dupilumab-induced ocular surface disease (DIOSD) has been reported in patients with atopic dermatitis treated with dupilumab, and has been recognized as an adverse event of dupilumab. Our objective was to describe two cases of DIOSD with alterations in eotaxin-2 and interleukin (IL)-8 me...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526929/ https://www.ncbi.nlm.nih.gov/pubmed/36184619 http://dx.doi.org/10.1186/s13223-022-00727-6 |
_version_ | 1784800979050299392 |
---|---|
author | Adachi, Rumi Shoji, Jun Hirota, Akira Tomioka, Akiko Tonozuka, Yukiko Inada, Noriko Yamagami, Satoru |
author_facet | Adachi, Rumi Shoji, Jun Hirota, Akira Tomioka, Akiko Tonozuka, Yukiko Inada, Noriko Yamagami, Satoru |
author_sort | Adachi, Rumi |
collection | PubMed |
description | BACKGROUND: Dupilumab-induced ocular surface disease (DIOSD) has been reported in patients with atopic dermatitis treated with dupilumab, and has been recognized as an adverse event of dupilumab. Our objective was to describe two cases of DIOSD with alterations in eotaxin-2 and interleukin (IL)-8 messenger ribonucleic acid (mRNA) expression on the ocular surface. CASE PRESENTATION: In the ocular surface test, specimens were collected from the patient's ocular surface, and eotaxin-2 and IL-8 mRNA levels in the specimens were measured using real-time polymerase chain reaction. The clinical score of ocular surface findings was quantified using a 5-5-5 exacerbation grading scale for allergic conjunctivitis. The first case was of a 27-year-old man who developed DIOSD 3 months after starting treatment with dupilumab injection for atopic dermatitis. After 5 weeks of topical instillation of tacrolimus ophthalmic suspension, the clinical score of ocular surface findings improved and IL-8 and eotaxin-2 mRNA expression levels gradually decreased. The second patient was a 55-year-old man who developed DIOSD 11 weeks after the start of treatment with dupilumab injection for atopic dermatitis. Four weeks after starting ophthalmological treatment with tacrolimus ophthalmic suspension, his clinical scores on ocular surface findings improved and IL-8 mRNA expression levels decreased. The ocular surface test in this case revealed increased expression levels of IL-8 mRNA on the ocular surface at the onset of DIOSD, which decreased with the improvement of objective findings. CONCLUSIONS: DIOSD, which has been successfully treated with tacrolimus ophthalmic suspension, may involve IL-8-related inflammation in addition to type 2 inflammation. |
format | Online Article Text |
id | pubmed-9526929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95269292022-10-03 Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report Adachi, Rumi Shoji, Jun Hirota, Akira Tomioka, Akiko Tonozuka, Yukiko Inada, Noriko Yamagami, Satoru Allergy Asthma Clin Immunol Case Report BACKGROUND: Dupilumab-induced ocular surface disease (DIOSD) has been reported in patients with atopic dermatitis treated with dupilumab, and has been recognized as an adverse event of dupilumab. Our objective was to describe two cases of DIOSD with alterations in eotaxin-2 and interleukin (IL)-8 messenger ribonucleic acid (mRNA) expression on the ocular surface. CASE PRESENTATION: In the ocular surface test, specimens were collected from the patient's ocular surface, and eotaxin-2 and IL-8 mRNA levels in the specimens were measured using real-time polymerase chain reaction. The clinical score of ocular surface findings was quantified using a 5-5-5 exacerbation grading scale for allergic conjunctivitis. The first case was of a 27-year-old man who developed DIOSD 3 months after starting treatment with dupilumab injection for atopic dermatitis. After 5 weeks of topical instillation of tacrolimus ophthalmic suspension, the clinical score of ocular surface findings improved and IL-8 and eotaxin-2 mRNA expression levels gradually decreased. The second patient was a 55-year-old man who developed DIOSD 11 weeks after the start of treatment with dupilumab injection for atopic dermatitis. Four weeks after starting ophthalmological treatment with tacrolimus ophthalmic suspension, his clinical scores on ocular surface findings improved and IL-8 mRNA expression levels decreased. The ocular surface test in this case revealed increased expression levels of IL-8 mRNA on the ocular surface at the onset of DIOSD, which decreased with the improvement of objective findings. CONCLUSIONS: DIOSD, which has been successfully treated with tacrolimus ophthalmic suspension, may involve IL-8-related inflammation in addition to type 2 inflammation. BioMed Central 2022-10-02 /pmc/articles/PMC9526929/ /pubmed/36184619 http://dx.doi.org/10.1186/s13223-022-00727-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Adachi, Rumi Shoji, Jun Hirota, Akira Tomioka, Akiko Tonozuka, Yukiko Inada, Noriko Yamagami, Satoru Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report |
title | Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report |
title_full | Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report |
title_fullStr | Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report |
title_full_unstemmed | Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report |
title_short | Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report |
title_sort | two cases of dupilumab-associated conjunctivitis with high expression of il-8 mrna on the ocular surface: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526929/ https://www.ncbi.nlm.nih.gov/pubmed/36184619 http://dx.doi.org/10.1186/s13223-022-00727-6 |
work_keys_str_mv | AT adachirumi twocasesofdupilumabassociatedconjunctivitiswithhighexpressionofil8mrnaontheocularsurfaceacasereport AT shojijun twocasesofdupilumabassociatedconjunctivitiswithhighexpressionofil8mrnaontheocularsurfaceacasereport AT hirotaakira twocasesofdupilumabassociatedconjunctivitiswithhighexpressionofil8mrnaontheocularsurfaceacasereport AT tomiokaakiko twocasesofdupilumabassociatedconjunctivitiswithhighexpressionofil8mrnaontheocularsurfaceacasereport AT tonozukayukiko twocasesofdupilumabassociatedconjunctivitiswithhighexpressionofil8mrnaontheocularsurfaceacasereport AT inadanoriko twocasesofdupilumabassociatedconjunctivitiswithhighexpressionofil8mrnaontheocularsurfaceacasereport AT yamagamisatoru twocasesofdupilumabassociatedconjunctivitiswithhighexpressionofil8mrnaontheocularsurfaceacasereport |